Pharmaceuticals
Novartis has a well-earned reputation for introducing innovative and effective medicines for disease areas in need of new therapies - particularly in oncology, transplantation and ophthalmology. We are also known for producing new and ever-more efficient medicines for the more common cardiovascular and respiratory diseases, as well as for diseases affecting the brain.
Novartis currently has a total of 75 development projects in the pipeline, of which 70% are in trial phases II or III, or in registration. 90% of these projects offer new modes of action or are treatments meeting unmet clinical needs.
In 2006, Novartis commitment to research and product innovation was recognised worldwide, with the Scrip Award for best product pipeline within the pharmaceutical industry.
The pharmaceuticals division is divided into:
Novartis General Medicines
- Cardiovascular and Metabolism
Hypertension, Diabetes, Atherosclerosis - Neuroscience
Alzheimer’s, Parkinson’s, Epilepsy, Depression, Schizophrenia, Anxiety, Chronic Pain, Multiple sclerosis - Respiratory
Asthma, COPD, Allergies, Bronchitis, Cystic Fibrosis - Dermatology
Onychomycosis (fungal nail infection), Psoriasis, Atopic dermatitis, Acne - Infectious diseases, Transplantation and Immunology
Organ transplants - Ophthalmology
Age-related macular degeneration, Dry eye
Product Information for Patients & Carers
Comprehensive information about common medical conditions, medication and other health concerns.
Clinical Trials
Clinical trials are designed to find better ways to treat or prevent diseases.
Find out more about ongoing clinical trials or view the results of past trials here
Careers at Novartis
Our success depends on the creativity and performance of our associates.